173,350 Shares in Bristol Myers Squibb Company $BMY Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, Holdings Channel reports. The firm bought 173,350 shares of the biopharmaceutical company’s stock, valued at approximately $9,988,000.

Several other institutional investors have also recently made changes to their positions in the company. Leigh Baldwin & CO. LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at approximately $530,000. Osmosis Investment Management UK Ltd acquired a new stake in Bristol Myers Squibb during the second quarter worth $16,671,000. Sanctuary Advisors LLC purchased a new stake in Bristol Myers Squibb in the second quarter valued at $22,137,000. Barbara Oil Co. purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter worth $2,420,000. Finally, Saranac Partners Ltd acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth about $421,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $67.30 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The firm has a market cap of $137.47 billion, a PE ratio of 14.82, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company’s 50 day moving average is $60.77 and its two-hundred day moving average is $59.47.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BMY shares. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, Piper Sandler initiated coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an “overweight” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.